Table 1. General characteristics of included studies in the meta-analysis.

Author	Year	5-year OS (%)	5-year LC (%)	Disease-free progression (%)	Lymph node positive	Sample size
Crook et al.	2009	81	88	70	0.08	60
Soria et al.	1997	63	77	54	0.23	72
Delaunay et al.	2013	81	84	-	0.00	47
Rozan et al.	1995	68	78	59	0.19	174
Chaudhary et al.	1999	72	70	78	0.35	23
Garcia et al.	2012	82	76	71	0.00	21
Mazeron et al.	1984	79	78	76	0.10	50
Delannes et al.	1992	85	82	83	0.24	51
Kiltie et al.	2000	69	81	76	0.00	31
De Crevoisier et al.	2009	-	80	86	0.18	144
Cordoba et al.	2016	82	74	64	0.38	73
Guimaraes et al.	2009	84	83	76	0.24	333
Lont et al.	2006	-	88	88	0.17	100
Ozsahin et al.	2006	53	88	87	0.30	23
Zouhair et al.	2001	61	75	75	0.29	29
Mistry et al.	2007	83	88	87	0.23	24
Kattan et al.	2006	58	-	-	0.20	175
Phillippou et al.	2008	89	86	75	0.28	179
Omellas et al.	2008	75	-	75	0.44	642
Du et al.	2003	38	-	38	0.13	76
Lei et al.	2016	78	-	85	0.16	129
Kong et al.	2002	80	-	78	0.24	104

5-year OS, 5-year overall survival; 5-year LC, 5-year local control.